Trial | NCT01636505  Report issue

Title

The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    200
The aim of this study is to performed a randomized controlled trial to evaluate the rate of genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocols.

Patients will be prospectively randomized in two groups: the first undergoing controlled ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist ovarian stimulation regimen.

The end-points of the study include the number of genetically and chromosomally abnormal embryos, the pregnancy, the implantation and the healthy baby birth rate.

The patients included in PGS program were selected on the base of advanced maternal age, repeated pregnancy lost and implantation failure whereas the patients who were know to carry sex-linked or monogenic disorders were considered for PGD strategy.

The uterine abnormalities, endometriosis and endocrinal diseases were considered to be the exclusion factors.
Study Started
Sep 30
2012
Primary Completion
Feb 28
2013
Anticipated
Study Completion
Sep 30
2013
Anticipated
Last Update
Jul 10
2012
Estimate

Drug ghrh antagonist (cetrotide/orgalutran)

cetrotide/orgalutran 0.25 mg

Drug gnrh agonist (suprefact)

suprefact 5.5 ml

short protocol Active Comparator

gnrh agonist versus gnrh antagonist

long protocol Active Comparator

Criteria 

Inclusion Criteria:

patients carrier genetic disease
advanced maternal Age
repeated IVF failure
recurrent pregnancy loss

Exclusion Criteria:

uterine abnormalities
endometriosis
endocrinal diseases
No Results Posted